Navigation Links
COPD Patients portray improved exercise performance after breathing a Special Gas

Here is a breather for those who suffer from severe chronic obstructive pulmonary disease (COPD). A new finding has revealed that breathing a special gas mixture may help in drastic improvement// of exercise performance in such individuals. Patients revealed that after breathing the gas, their endurance walking test improved nearly 64% with less shortness of breath. These findings have been published in the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Elizabeth A. Laude, Ph.D., of the University of Sheffield in the United Kingdom, and seven associates studied the effects of varying oxygen and helium levels in the air breathed during exercise by 82 patients who had severe, but stable COPD. Four different gas mixtures were used to test the patients, 72 percent helium and 28 percent oxygen (Heliox28); 79 percent helium and 21 percent oxygen (Heliox21); 72 percent nitrogen and 28 percent oxygen (Oxygen28); and 79 percent nitrogen and 21 percent oxygen (medical air).

Researchers were optimistic of bringing down the airway resistance by substituting the normal supplementary oxygen with lower density helium gas, "COPD is associated with impaired exercise capacity, which contributes significantly to a reduced quality of life in these patients," said Dr. Laude.

It was observed that Individuals with the worst lung function test results portrayed the highest benefit from the special mixtures.

Dr Laude said "Although the recent American Thoracic Society/European Respiratory guidelines had recognized COPD is a preventable and treatable condition, it is still regarded by many as one in which significant improvement is not possible. Our data shows this is not the case. The changes in endurance exercise and reductions in breathlessness we report while breathing increased inspired oxygen or heliox gas mixtures are substantial, being at least comparable to those achieved with curre
'"/>




Page: 1 2

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
(Date:12/5/2008)... RICHMOND HILL, ON, Dec. 5 /PRNewswire/ - Norgine,...pany, has today announced that it has granted Medi...P(R) in Canada. , MOVIPREP is a novel patent-pr...ansing prior to colonoscopy and other situations w...keted by Norgine in Europe and in the USA by its p...
(Date:12/5/2008)... BELLUS Health Receives NASDAQ Deficiency Notice R...--------------------------------------------------...ll/ - BELLUS Health Inc. (NASDAQ: BLUS ; TSX: BL...nt fluctuations in world capital markets, the Comp...SDAQ Capital Market, while continuing to maintain ...
(Date:12/5/2008)..., Dr. Alan Greene from th...ar milestone of eating only organic food. It,s the...tified 100% organic. , Da... animals can be certified organic by the Departmen...n and author Dr. Alan Greene, why not people?, , ,...
(Date:12/4/2008)..., Early detection of lung disease in cystic fibro...fants, may be the key to controlling the progressi...w research shows that contrary to previous scienti...s can begin as early as infancy even though lung f...e might be able to stop some of the lung function ...
Breaking Medicine News(10 mins):Health News:Medical Futures partners with Norgine for MOVIPREP(R) in Canada 2Health News:BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market 2Health News:BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market 3Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 2Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 3Health News:Intervention in infants with cystic fibrosis key to slowing progression 2Health News:Intervention in infants with cystic fibrosis key to slowing progression 3
...e WHO has issue a checklist for doctors and nurse ...s. Basic mistakes like not washing hands by the h...arters. The WHOs 9 solution is meant to improve p...essen the number of health care related accidents ...
...e Delhi High Court Wednesday held that the misuse ...taff would be viewed seriously, stressing that th...ision bench of Justice T.S. Thakur and Justice S.N... of the hospitals of both state and central govern...
...California-based Keralite doctor has bagged this y...the National Ethnic Coalition of Organisations (NE... award May 12, said he was "really delighted". "Th...o be a boost for all my future endeavours," Eapen ...
...ldiers returning from Iraq who have migraine heada...mptoms of post-traumatic stress, depression or anx...ording to research. The study involved 3,621 Unite...en a health screening questionnaire within 90 days...
Other Medicine News:Health News:UN Agencys Checklist on Health Care Error 2Health News:Migraines may Be a Symptom of Other Problems for Iraq Soldiers 2
(Date:12/3/2008)..., Dec. 3 Isogen, a contract develo...filling, announced it has retained a,strategic fi...et the global,biopharma demand for Isogen,s servi...ccessful first round series of capital,investment...y in Q1 2009 to,deliver on the previously unmet p...
(Date:12/3/2008)...Calif., Dec. 3 Bionovo, ...DA has reviewed the company,s,manufacturing and c...d,guidance on how Bionovo can move forward with t...for menopausal hot flashes. , "We have conc...moving to,address the Agency,s recommendations fo...
(Date:12/2/2008).... 3 Researchers using f...cuitry in the area of the brain,responsible for s...fering from,stress-related psychiatric disorders....the annual meeting of the Radiological Society of ... major depression and other stress-related disorde...
(Date:12/2/2008)...ass., Dec. 2 Biopure Cor...he U.S. Naval Medical Research Center,(NMRC) has ...) a revised,investigational new drug (IND) applic...s oxygen therapeutic Hemopure(R) [hemoglobin gluta...eld treatment of trauma patients. The study is,en...
Breaking Medicine Technology:Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 2Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 3Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings 4Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3BrainCells Inc Completes 2430 Million Initial Closing of Series B Financing 3816 1BrainCells Inc Completes 2430 Million Initial Closing of Series B Financing 3816 2Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 1Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 2Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 3Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 4Sunesis Pharmaceuticals Reports Positive Interim Data for SNS 595 Single Agent Activity in Platinum Resistant Ovarian Cancer 1485 5Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 1Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 2Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 3Palatin Technologies Inc Reports Positive Results of a Phase I Clinical Study With PL 3994 for the Treatment of Congestive Heart Failure 3811 4Fralex reaches 100th patient milestone in fibromyalgia study 3810 1Fralex reaches 100th patient milestone in fibromyalgia study 3810 2Fralex reaches 100th patient milestone in fibromyalgia study 3810 3
...pril 2007. Giaconda Ltd (ASX: GIA) today,announced...s,approved the Company,s Investigational New Drug ...MyocondaR to treat patients with,Crohn,s Disease i...sis (MAP). , ,The Company understands that its lea...ubmitted to the FDA for this indication. There,are...
... 160th Annual Meeting of the American,Psychiatric ...-FirstCall/ -- In adults with,major depressive dis...py (ADT) resulted in significant improvement in th...ion Rating Scale (MADRS),Total Score. In this six-...ed here at the 160th Annual Meeting of the America...
Other Medicine Technology:FDA approves MyocondaR IND for MAP in Crohn's Disease 2FDA approves MyocondaR IND for MAP in Crohn's Disease 3FDA approves MyocondaR IND for MAP in Crohn's Disease 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8
Low-profile, hand-held instrument.
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries.
The Smith & Nephew ECTRA II systems permit the surgeon to access and release the carpal tunnel ligament endoscopically, allowing access via two portals for distal and proximal cutting, while minimizi
The Stryker AZTEC Shoulder Holder is used for positioning the patients arm during surgery in the lateral position. The shoulder holder is adjustable with respect to height and rotation for all arm po
Medicine Products: